BioSpace News Archive

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced the publication of the Phase 3 VITAL clinical trial in Blood, a journal of the American Society of Hematology (ASH).

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Centene Corporation (NYSE: CNC) today announced that it will release its 2023 second quarter financial results at approximately 6 a.m. (Eastern Time) on Friday, July 28, 2023, and will host a conference call afterwards at approximately 8:30 a.m. (Eastern Time) to review the results.

Vistagen (NASDAQ: VTGN) today announced it will host a conference call and webcast on Wednesday, June 28, at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to report results for its fiscal year 2023 ended March 31, 2023 and provide a corporate update.

Anbio Biotechnology (Anbio), a leading global diagnostic device and assay company, has announced its participation in the 2023 American Association for Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo from July 25th to 27th in Anaheim, CA where it will be officially launching its brand in North American market.

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (the “Company”), a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), is pleased to announce the results of its annual general and special meeting of shareholders (the “Meeting”) held earlier today.

Genmab A/S and AbbVie announced topline results from the follicular lymphoma cohort of the phase 1/2 EPCORE™ NHL-1 clinical trial evaluating epcoritamab, an investigational T-cell engaging bispecific antibody administered subcutaneously.

Reata Pharmaceuticals, Inc. announced that the United States Food and Drug Administration has approved the Prior Approval Supplement to update the drug substance specification for SKYCLARYS®, the first and only FDA approved drug for the treatment of Friedreich’s ataxia in adults and adolescents aged 16 years and older.

Axsome Therapeutics, Inc. announced that it intends to offer and sell shares of its common stock, subject to market and other conditions, in an underwritten public offering.

Sihuan Pharmaceutical Holdings Group Ltd. together with its subsidiaries, is pleased to announce that Xuanzhu Biopharmaceutical Co., Ltd., a non-wholly owned subsidiary of Company, has received a drug registration approval from the National Medical Products Administration of China of Anaprozole Sodium Enteric-coated Tablet for the treatment of duodenal ulcer.